Welcome! It's on Friday 18th April 2014

Pharmacy

  • CAPS babies can now be treated at home

    A first of its kind treatment for babies as young as eight months who have cryopyrin-associated periodic syndromes (CAPS) has just been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for use in the UK.

  • Humira recommended in Wales

    The All Wales Medicines Strategy Group has recommended AbbVie’s Humira (adalimumab) as an option for use in NHS Wales.

  • EU gives Celgene go-ahead for Revlimid

    The European Commission has granted approval to Revlimid (lenalidomide) for the treatment of patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are failing.

  • Peter Dodds

    Peers debate patient choice

    The debate over a pharmacy law that forces patients away from GPs who dispense pharmaceuticals is heating up in the House of Lords with a series of questions from five peers to Earl Howe, England’s pharmacy minister.

  • Neal Patel

    Free prescriptions should be norm for LTCs

    People who have long-term conditions should all be able to get their prescription medicines free of charge, finds a report just published by the Prescription Charges Coalition.

  • Dr Val Harpin, Consultant Neurodevelopmental Paediatrician

    MHRA gives go-ahead for ADHD drug therapy

    Healthcare practitioners treating children who have attention deficit/hyperactivity disorder (ADHD) will soon have a new treatment option called Elvanse (lisdexamfetamine dimesylate) from Shire UK.